Business Context and Reporting Period
This Form 6-K is filed by Galapagos NV, a foreign private issuer, for the month of October 2019. The filing, dated October 7, 2019, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant's principal executive office is located in Mechelen, Belgium. Note: The request metadata references "Lakefront Biotherapeutics NV," but the filing text explicitly identifies the registrant as Galapagos NV.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to distribute a press release and does not contain a financial statement or quantitative data table.
Material Changes
The filing does not disclose specific material changes in financial position or operations within the text provided. The primary purpose is to disseminate the content of the attached press release (Exhibit 99.1), the details of which are not included in the provided text.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, risk factors, or descriptions of contingencies. These elements, if present, would be contained within the referenced Exhibit 99.1 press release, which is not part of the input text.
Investor Verification Checklist
- Verify the actual content of the press release dated October 7, 2019 (Exhibit 99.1), as the filing text only references it.
- Confirm the correct registrant name is Galapagos NV, not Lakefront Biotherapeutics NV.
- Review the incorporated Registration Statements (Forms F-3 and S-8) for broader context on capital raising activities.
- Check for subsequent filings if the press release contained material updates on clinical trials or partnerships.